The recent CMS coverage determination did not make any mention of beta-amyloid PET imaging that is necessary for both diagnosing Alzheimer’s and monitoring the effectiveness of related treatments.
The findings support adopting F-18 DCFPyL PET/CT as the standard of care for prostate cancer staging, authors of a new Scientific Reports paper concluded.
Rather than administering radiolabeled glucose for exams, imagers give patients a small amount of a harmless glucose solution that is said to be equivalent to a can of a carbonated drink.
Difficulty obtaining PET/CT scans was reported by 55% of respondents, with 21% citing this as the greatest barrier in treating classic Hodgkin lymphoma.
The AUC includes a total of 32 clinical scenarios that have been grouped into four categories of cancer: breast, skin, cancer of other sites and lymphedema.
The NRC noted that advancements in nuclear medicine and increased use of radiopharmaceuticals prompted the commission to reconsider the exclusion of extravasation from medical event reporting.
Prior to the Dec. 15 announcement, CMS had released a different statement in June informing the public that they were reconsidering the amount of PET scans that Alzheimer’s patients undergoing monoclonal antibody treatment can receive.
The radiotracer, 68Ga-PentixaFor, can be used for detecting C-X-C motif chemokine receptor 4 (CXCR4), which plays a significant role in cancer progression.
Common markers of Alzheimer's disease visualized on PET scans of asymptomatic patients might foreshadow the onset of symptoms in the years following their initial discovery.
Recently, a patent for 3D printed uranium targets was secured by the National Center for Nuclear Research (NCBJ) in Swierk, Poland, and it could increase the production of Molybdenum-99 (Mo-99) globally.
The 36,000 square foot unit will be located in Beloit, Wis., alongside NorthStar’s production facilities. It is expected to be open for business starting in 2024.
